Recorded Future Unveils Key Note Lineup for Annual Summit Showcasing the "The Future of Intelligence"

LONDON, Oct. 30, 2023 /PRNewswire/ —  Recorded Future, the world’s largest intelligence company, today announced the keynote speaker lineup for its global, annual intelligence summit, PREDICT 2023, being held November 14 in London, GB at Kings Place. Focused on "Securing Tomorrow: The Future of Intelligence," PREDICT 2023’s final global installment in London brings together thought leaders and innovators from both public and private sectors to discuss the present threat landscape and future trajectory of intelligence.

The speaker lineup for PREDICT London 2023 includes:

The Rt Hon Tom Tugendhat MBE VR MP, Security Minister, United Kingdom General Sir Jim Hockenhull, KBE ADC Gen, Commander of UK Strategic Command Sir Alex Younger, Former MI6 Chief Espen Johansen, CSO at Visma Nicholas Moch, Head of SEBx Christian Karam, Executive at Hakluyt

Recorded Future executive speakers include:

Christopher Ahlberg, PhD – CEO and Co-Founder of Recorded Future Staffan Truvé – CTO and Co-Founder of Recorded Future Jason Steer – CISO of Recorded Future Levi Gundert – CSO of Recorded Future Allan Liska – CSIRT at Recorded Future Kalpana Singh – VP, Product Marketing Jamie Zajac – VP, Product Management

"Building on Recorded Future’s mission to secure the world with intelligence, we are excited to unite intelligence visionaries and pioneers at this year’s annual global summit to foster collaboration within our community. In today’s digital era, with technology evolving rapidly, vigilance against security threats is paramount. It is our belief that together, we can better disrupt our common adversaries. PREDICT London 2023’s insightful discussions will shine a spotlight on the complexities of the current threat landscape and will demonstrate how emerging technologies such as AI and machine learning can help prepare for the threats of tomorrow."  — Dr. Christopher Ahlberg, CEO and Co-Founder, Recorded Future

PREDICT London 2023 is open to intelligence analysts, network defenders, cybersecurity leaders, and others interested in learning about intelligence-led security.

For more information visit: https://www.recordedfuture.com/predict/.

For real-time updates on #PREDICT2023 sessions, follow @RecordedFuture on X (formerly Twitter).

For all the latest breaking news and reports from #PREDICT2023, follow @TheRecord_Media on X (formerly Twitter).

About Recorded Future
Recorded Future is the world’s largest threat intelligence company. Recorded Future’s Intelligence Cloud provides end-to-end intelligence across adversaries, infrastructure, and targets. Indexing the internet across the open web, dark web, and technical sources, Recorded Future provides real-time visibility into an expanding attack surface and threat landscape, empowering clients to act with speed and confidence to reduce risk and securely drive business forward. Headquartered in Boston with offices and employees around the world, Recorded Future works with over 1,700 businesses and government organizations across more than 75 countries to provide real-time, unbiased, and actionable intelligence. Learn more at recordedfuture.com.

Source : The World's Leading Intelligence Summit Returns to London for Predict 2023

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

FRISCO, Texas, Oct. 30, 2023 /PRNewswire/ — Olight, a leading mobile lighting manufacturer, successfully concludes its 2023 Breast Cancer Charity Campaign, raising $77,313.43 for breast cancer support across 13 countries, including the USA, UK, Canada, Korea, Thailand, Italy, Germany, France, Australia, Japan, Spain, Austria, and China, thanks to all buyers of Olight charity products.

Olight received the third Anniversary Partner Award from NBCF

From October 24 to 26, OlightUSA offered four flashlight models (imini 2 Pink, Gober, Obulb pro S, and Wyvern Pink) for sale on olightstore.com. Olight websites in other countries also launched sales respectively. All proceeds were dedicated to the National Breast Cancer Foundation (NBCF) in the USA and other global partners, such as Brustkrebs Deutschland e.V. in Germany and Australia National Breast Cancer Foundation. Over the past three years, Olight has raised $518,930, directly impacting over 10,000 patients globally for breast cancer.

A notable addition this year was an offline setting in the USA: Olight established an Awareness Booth in Frisco, Dallas, in partnership with NBCF. This booth provided breast cancer information and fostered community participation against the disease. Olight also gifted volunteers and patients with special flashlights, pink pouches, etc. on site. Additionally, 300 patients will receive Olight flashlights and other gifts in HOPE Kits.

During the event, Olight received the prestigious third Anniversary Partner Award from NBCF, recognizing its unwavering commitment to the cause. Mavis Xiao, Vice President of Olight, said, "It’s a honor to stand by NBCF in this mission for three years. As a global corporate citizen, Olight aims not only to illuminate the world with lighting, but also to infuse it with HOPE."

The collaboration between Olight and partners, such as NBCF, facilitated vital conversations about early detection and treatment, emphasizing the significance of awareness and community engagement. Brooke Adams, Sr. Director of Charitable Giving and Strategic Partnerships at NBCF, expressed thanks for Olight’s dedication and anticipated further collaborations.

Breast cancer remains a global concern, and Olight will continuously provide support and hope to those affected with global partners.

Olight

Olight is a leading provider of portable lighting solutions, dedicated to its mission of "illuminating the world". It’s diverse range of products serves various scenarios, including household, outdoor, and other applications, with products that are sold and utilized worldwide across Europe, the Americas, and other regions worldwide.

For more information about Olight, please visit www.olightworld.com.

Source : Olight 2023 Breast Cancer Charity Campaign: Illuminating Hope with Breast Cancer Foundations Across the World

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

The Month’s Robust Revenue from the 5G Business Segment is Expected to be Sustainable through Fiscal Year 2024

BEIJING, Oct. 30, 2023 /PRNewswire/ — Datasea Inc., (NASDAQ: DTSS) ("Datasea" or the "Company"), a Nevada incorporated digital technology corporation engaged in converging and innovative business segments for intelligent acoustics and 5G messaging technology in China, today announced that it recorded revenue of RMB 17.8 million (US $2.5 million) in the month of September 2023, attributable to three of its 5G business segment operating entities. The Company’s September 2023 5G messaging revenue was 12x greater than 5G messaging revenue in September 2022 which came in at RMB 0.15 million (US $0.02 million).

Datasea CEO, Ms. Zhixin Liu, commented, "Our 5G messaging business has recovered rapidly so far this year relative to somewhat discouraging results last year. We signed major contracts beginning in June 2023 that we think could create momentum for this business segment going forward."

"We provide 5G messaging products to both corporate customers and household users that offers enhanced 5G capabilities in the Chinese market. The features of our messaging products include rich media, strong interactivity, excellent transmission quality and high security for an improved customer experience. As a leading service provide in China’s 5G communications field, we have unique and scalable products that enhance our market competitiveness and positions us for future growth," Ms. Liu concluded.

Datasea’s 5G operating subsidiaries operate in various industry sectors, including chain retail, Internet and intelligent hardware. The Company serves a diverse and geographically dispersed customer base in China, offering clients comprehensive 5G messaging services, including multiple top-up plans, data interfaces, and a streamlined 5G messaging payment platform.

About Datasea Inc.

Datasea Inc. ("Datasea") is a leading provider of products, services, and solutions for enterprise and retail customers in converging and innovative industries, Intelligent Acoustics and 5G messaging, especially focusing on ultrasonic, infrasound and directional sound technology. The Company’s advanced R&D technology serves as the core infrastructure and backbone for its products. Its 5G Messaging segment operates on a cloud platform based on AI. Datasea leverages cutting-edge technologies in intelligent acoustics, utilizing ultrasonic sterilization to combat viruses and prevent human infections, and is also developing innovations in directional sound and medical ultrasonic cosmetology. In July 2023, Datasea established a wholly-owned subsidiary, Datasea Acoustics LLC, in Delaware, in a strategic move to mark its global presence. This underlies Datasea’s commitment to Intelligent Acoustics and its intent to offer leading edge acoustic solutions to the US market. For additional information, please visit: www.dataseainc.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will", "expects", "anticipates", "future", "intends", "plans", "believes", "estimates", "target", "going forward", "outlook," "objective" and similar terms. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and which are beyond Datasea’s control, which may cause Datasea’s actual results, performance or achievements  (including the RMB/USD value of its anticipated benefit to Datasea as described herein) to differ materially and in an adverse manner from anticipated results contained or implied in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in Datasea’s filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. Datasea does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

Investor and Media Contact: 

Datasea Inc. Investor relations
Email: [email protected]

Source : Datasea Announces September 2023 Revenue of $2.5 million from its 5G Messaging Business

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

– Global No.1 Kimchi Brand ‘JONGGA’ and the Institute of Culinary Education (ICE), SF Globalize Inc., KCCNY joins forces to hold the JONGGA Kimchi Cook-off

– Jongga celebrates Jongga Kimchi Blast kimchi-making event at the New York Korean Festival, and donations were delivered to spread the culture of harmony and sharing

NEW YORK, Oct. 30, 2023 /PRNewswire/ — Sangtae JU (Founder of Kimchi Cook-off), Jennifer LEE (Head of of Global Food Business Unit, Daesang) and Richard La Marita (ICE’s Head Chef) pose for a photo with the winners of the 2023 JONGGA Kimchi Cook Off in NY at ICE on October 26.

Sangtae JU (Founder of Kimchi Cook-off), Jennifer LEE( Head of of Global Food Business Unit, Daesang) and Richard La Marita( ICE’s Head Chef) pose for a photo with the winners of the at ICE on October 26.

Sponsored by Jongga, the No.1 kimchi brand in Korea since 1987, the Jongga Kimchi Blast in the United States was previously held in California, but this year it was held for the first time in New York. Co-hosted by the prestigious U.S. culinary school ICE (Institute of Culinary Education), SF Globalize, and the Korean Cultural Center NY, it ended successfully in New York, USA.

Held annually in three countries, France, United Kingdom, and United States, the Jongga Kimchi Blast is an event designed to promote the excellence of Jongga kimchi around the world. In the United States, it was previously held in California, but this year it was held for the first time in New York following Paris and London in July.

At the Jongga Kimchi Cook Off held at ICE on 26th Oct, eight finalists were competing with a high competition rate of 45:1. Participants from various backgrounds, including teachers, engineers, and designers, as well as incumbent chefs, introduced novel kimchi recipes across the U.S.

The judges, including Richard La Marita, vice president of ICE, lead chef Chaynin Pornsriniyom, television host and actress Marja Vongerichten, reviewed the creativity, popularity, artistry, and suitability of each dish with kimchi as a main ingredient.

The final championship was won by Chef HWANG’s ‘Red Snapper Kimchi Jjigae with fish cake stuffed morel mushroom and Cherry tomato with White Kimchi yuzu water’ living in New York. The second place was given to G HAN’s ‘Kimchikópita’ from Minnesota, the third place to JAEHWAN KIM’s ‘Kimchi nurungji paella & Red snapper ceviche’, and the Jongga special prize was honored to MINH NGUYEN’s ‘Kimchi Infused Pork Belly’.

The kimchi-making event in the New York Korean Festival, held at Union Square Park on 29th Oct, was also hot. It was an event to promote Korea’s kimchi culture and the spirit of sharing, and a total of 300 participants experienced the kimchi culture by mixing the seasoning with the napa cabbage by themselves. Jongga also donated $3,000 each to the New York Women’s Foundation(NYWF), the New York Fire Department(FDNY), and the Korean American Family Service Center(KAFSC).

In addition, various activities were carried out for visitors of the New York Korean Festival, including introducing diverse Korean food products of O’Food, a global sister brand of Jongga, operating booths where they can taste the products and participating in a social media event.

Jennifer Lee, Head of Global Food Business Unit, Daesang, for Jongga, said: "Jongga Kimchi Blast in New York was an opportunity to promote the excellence of Jongga Kimchi and to confirm its global popularity. We hope participants come away knowing more about Kimchi, including its versatility and gut-health benefits, and ultimately feel more confident to cook with it at home as part of their everyday meals."

Sangtae JU, The founder of the Kimchi Cook-Off, said: "Koreans have enjoyed Kimchi for over 1000 years, Kimchi transforms the humble cabbage through fermentation with salt, and a few carefully selected aromatics and ingredients. As well as preserving, and creating an amazing taste, the fermentation process brings a wealth of health benefits – it improves the bioavailability of many vitamins and nutrients by producing foods the body finds easier to digest.

We plan to continue to expand and organize Kimchi Cook-off in cities around the world, including Paris, London, and New York, with people who love to cook and are health conscious. We look forward to your interest and participation next year."

Source : The JONGGA Kimchi Cook-off, a favorite in Paris and London, has finally touched down in NYC

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

CHANGSHA, China, Oct. 30, 2023 /PRNewswire/ — SANY Group (SANY), a leading global machinery manufacturer, has launched five all-new small excavator products with fully elevated functionality and performance, which will officially go into the market in 2024.

SANY’s Kunshan Industrial Park

The SY60C, SY75C, SY80U, SY95C, and SY135C, developed for the European and North American markets, have rolled off the assembly line at SANY’s industry park in Kunshan, Jiangsu Province, marking a milestone of SANY’s overseas product strategy.

Aiming to enhance SANY’s competitive advantages in the small excavator markets in Europe and the U.S., SANY has carried out in-depth surveys and research based on the needs, suggestions, and questions from markets outside China, and introduced Plan H – the High-Quality Plan (HQP) in July, which is composed of both product development and quality improvement projects.

"SANY’s international market strategy prioritizes product development as its foremost focus. The launch of five new products by SANY not only strengthens its position in the international market but also drives the overall product development of the entire series", said Chen Jiayuan, CEO of SANY Heavy Machine, a business division of SANY Heavy Industry.

Intelligent and safe with precision

The five small excavators highlight four major upgrades that comprehensively improve functionality, performance, maneuverability, and operation safety.

The enhanced configurations guarantee a more flexible, convenient, and safer operating experience, key upgrades include equipping two sets of auxiliary lines and one set of quick-change lines as well as a standard rear camera that offers a 15 percent better field of view. The standardized and serialized global product configurations for small excavators have also increased the product generalization rate to 75 percent.

The upgraded appearance of the new models not only improves the aesthetics. The 20 percent taller cover achieves smoother aerodynamics and brings up the product’s thermal balance by 8 percent. In the meantime, the new cabin is fully equipped with intelligent controls, Bluetooth, and multi-functional key panels. The cabin sealing rate is up by 20 percent.

The SY60C features a smart touch screen and ePower battery management module, an integrated one-touch start button and knob, an upgraded shovel that adapts to more construction conditions, and intelligent attachment matching for different customers and regions. The SY75C highlights elevated hydraulic performance – the end of the auxiliary line is upgraded to a ball diverter, and it’s equipped with the standard floating shovel function with a new valve spool for smoother compound actions. The new cabin interior setup has moved the foot valve front for more legroom. The SY80U has a multi-functional touch screen integrating the radio and air-conditioning control, the more convenient operation also matches the switching of 20 types of accessories. The optional 260-kg counterweight and 1.6-meter short bucket arm can increase the stability of the excavator and expand application scenarios to meet more project demands. The SY95C offers the options of an anti-explosive valve and quick-change line, with a standard floating shovel function, and the choices of a standard 1.7-meter and long 2.1-meter bucket arm to meet customers’ varied demands. Its upgraded driving gear has two options of steel or rubber tracks to meet the requirements of various road conditions, and the 450mm tall shovel improves bulldozing efficiency. The SY135C has an all-new armrest box design and interior color blend with a futuristic vibe. A hoisting function is available for this model, with dynamic and automatic weighing and lifting with an overload alarm to achieve intelligent, accurate, and safe operation.

SY135C

Source : SANY Launches Five New Small Excavators, Anchoring Future Development of International Market

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

STOCKHOLM, Oct. 30, 2023 /PRNewswire/ — Autoliv, Inc. (NYSE: ALV) and (SSE: ALIVsdb), the worldwide leader in automotive safety systems, today announces its intention to reduce its headcount in France as part of the previously announced initiatives to reduce its global headcount and to optimize its footprint. Today’s announcement is the final major communication related to the indirect headcount reduction initiative that was announced in June.

Aligned with previous communications, Autoliv continues to adapt and reduce its total workforce and to simplify its logistics and geographic footprint. These actions will significantly strengthen the company’s competitive position long-term, adapting it to a substantially lower level of light vehicle production in post-pandemic Europe.

Intended headcount reduction in France

Today, Autoliv announced its intention to reduce its workforce in France by about 20% or approximately 320 employees at its major plants in France. The company aims to initiate these reductions in the first half of 2024 and they are expected to be fully implemented by the end of 2025. The reduction is expected to affect 220 indirect employees mainly in production overhead but also within R,D&E and S,G&A. Additionally, as part of the footprint optimization, Autoliv intends to relocate its steering wheel manufacturing in France to other plants, affecting approximately 100 direct employees.

Specific measures will be defined in compliance with the local regulations and within the framework of a dialogue with elected representatives and the social partners to determine the most appropriate provisions for the employees concerned.

These actions in France are expected to generate savings of around $10 million in 2024, reaching around $20 million in 2025 and around $25 million in 2026 when fully implemented.

The related costs for the headcount reduction will be accrued this quarter. This will not impact the company’s adjusted operating margin for the fourth quarter or the full year 2023.

"By these actions, we continue to build our market leadership. Structural cost reductions, simplified logistics and an optimized industrial footprint significantly strengthen Autoliv’s competitive position long-term," says Magnus Jarlegren, President Autoliv Europe.

Total cost savings from announced structural cost reduction initiative in 2023

With this announcement, the total announced reductions of direct headcount are around 400 and more than 1,300 for indirect headcount. Total expected annual cost savings from these announcements amount to around $45 million in 2024, reaching $85 million in 2025, and $110 million when fully implemented.

Today’s announcement is the final major communication related to the indirect headcount reduction initiative that was announced in June, aiming for up to 2,000 indirect headcount reductions. Further reduction of global headcount as part of the initiative will be through minor actions and natural attrition with limited accruals. Related to such minor actions and natural attrition, we expect an additional reduction of around 250 indirect employees globally, in the near term.

Inquiries: 

Media: Gabriella Etemad, Tel +46 (70) 612 64 24
Investors & Analysts: Anders Trapp, Tel +46 (70) 957 81 71
Investors & Analysts: Henrik Kaar, Tel +46 (70) 957 81 14

About Autoliv

Autoliv, Inc. (NYSE: ALV; Nasdaq Stockholm: ALIV.sdb) is the worldwide leader in automotive safety systems. Through our group companies, we develop, manufacture and market protective systems, such as airbags, seatbelts, and steering wheels for all major automotive manufacturers in the world as well as mobility safety solutions, such as pedestrian protection, connected safety services and safety solutions for riders of powered two wheelers. At Autoliv, we challenge and re-define the standards of mobility safety to sustainably deliver leading solutions. In 2022, our products saved close to 35,000 lives and reduced more than 450,000 injuries.

Our close to 70,000 associates in 27 countries are passionate about our vision of Saving More Lives and quality is at the heart of everything we do. We drive innovation, research, and development at our 14 technical centers, with their 20 test tracks. Sales in 2022 amounted to US $ 8.8 billion. For more information go to www.autoliv.com.

Safe Harbor Statement

This report contains statements that are not historical facts but rather forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those that address activities, events or developments that Autoliv, Inc. or its management believes or anticipates may occur in the future. All forward-looking statements are based upon our current expectations, various assumptions and data available from third parties. Our expectations and assumptions are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that such forward-looking statements will materialize or prove to be correct as forward-looking statements are inherently subject to known and unknown risks, uncertainties and other factors which may cause actual future results, performance or achievements to differ materially from the future results, performance or achievements expressed in or implied by such forward-looking statements. Numerous risks, uncertainties and other factors may cause actual results to differ materially from those set out in the forward-looking statements, including general economic conditions and fluctuations in the global automotive market. For any forward-looking statements contained in this or any other document, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and we assume no obligation to update publicly or revise any such statements in light of new information or future events, except as required by law.

The following files are available for download:

https://mb.cision.com/Main/751/3865457/2393884.pdf

Autoliv Intends to Reduce Headcount in France

Source : Autoliv Intends to Reduce Headcount in France

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

National Comprehensive Cancer Network publishes free NCCN Guidelines for Patients with information on improving well-being and reducing suffering and distress for people with cancer; available at NCCN.org/patientguidelines.

PLYMOUTH MEETING, Pa., Oct. 30, 2023 /PRNewswire/ — The National Comprehensive Cancer Network® (NCCN®) is announcing new resources focused on improving quality of life for people with cancer while making sure care planning reflects individual needs and priorities. Today marks the publication of a new NCCN Guidelines for Patients®: Palliative Care, part of an ongoing expansion of supportive care resources. The new NCCN Guidelines for Patients: Fatigue and Cancer is also publishing, along with an updated book on managing Distress During Cancer Care.   

The NCCN Foundation®  provides funding for the NCCN Guidelines for Patients. All guides are available free-of-charge at NCCN.org/patientguidelines or via the NCCN Patient Guides for Cancer App.

"People with cancer should be able to live the best life possible. That means not just treating the cancer, but also helping people cope with any symptoms or hardships—both physical and emotional," said Gena Cook, CEO, Kaliper Health and Chair of the NCCN Foundation Board of Directors. "The NCCN Foundation is committed to providing tools that encourage and normalize conversations that put the emotional, social, and spiritual needs, values, beliefs, and cultures of the person with cancer and their caregivers at the center of any care plan."

"These guidelines will help enhance the quality of care and quality of life for individuals dealing with a diagnosis, and assist their families and caregivers as well," said Joanna Doran, CEO of Triage Cancer. "The experience is improved by focusing on the patient’s overall health and wellbeing, not just the treatment, and helping caregivers handle the side effects of managing the disease."

The NCCN Guidelines for Patients have received numerous awards for patient information, including a recent Excellence in Cancer Patient Education from the Cancer Patient Education Network (CPEN), founded by the National Cancer Institute (NCI). Independent studies have found them to be among the most-trustworthy sources for cancer information online.

NCCN Guidelines for Patients are based on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)—the gold standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine.

The patient guidelines contain the same evidence-based expert consensus treatment information as the clinical versions but are written specifically for people with cancer and their caregivers. Each book includes a glossary of medical terms and suggested questions to ask during appointments.

"There are many myths and less evidence-based approaches out there that patients may hear about or read about; the NCCN Guidelines for Patients steer them towards solutions that are supported by the best available evidence," explained Catherine Jankowski, PhD, University of Colorado Cancer Center, Chair of the NCCN Guidelines® Panel for Cancer-Related Fatigue. "For instance, when it comes to managing cancer-related fatigue, the evidence is squarely in favor of the benefits of physical activity, even at low levels."

Dr. Jankowski explained that NCCN’s various clinical practice guidelines for supportive care are designed in a coordinated fashion, noting, for example, that fatigue can cause distress and vice versa. Patients are sometimes surprised by how persistent cancer-related fatigue can be, and that it can arise at any time during or after treatment.

"Palliative care gives people a big picture view of what it’s like to navigate the cancer care experience across the scope of care, beginning with diagnosis," said Toby Campbell, MD, MS, University of Wisconsin Carbone Cancer Center, Vice-Chair of the NCCN Guidelines Panel for Palliative Care. "This is how the care team is able to represent each individual throughout a complicated series of events. These patient guidelines will help enable difficult conversations and affirm that people with cancer can make treatment choices based on what matters to them. Palliative care is also how we navigate symptoms and make it easier for patients to ‘weather the storm.’"

Dr. Campbell stressed that palliative care is an important part of comprehensive cancer care regardless of age, cancer stage, or the need for other therapies. He noted that recent studies have found that palliative care can often be delivered effectively through video visits, reducing the burden of patients needing to come into the clinic.

NCCN’s series of supportive care patient guidelines also includes books focused on side-effects from treatment, such as nausea and vomiting, blood clots, anemia, and immunotherapy-related adverse events. There are also survivorship guidelines featuring healthy living recommendations and information on addressing any long-term effects from cancer. The library of patient guidelines now includes 70 books in all, including guides to prevention, detection, and treatment for nearly every type of cancer—many are available in multiple languages.

Visit NCCN.org/patientresources to learn more about all of NCCN’s free resources for empowering people facing cancer and caregivers, including videos and webinars.

About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, equitable, and accessible cancer care so all patients can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) provide transparent, evidence-based, expert consensus recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients® provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation®. NCCN also advances continuing education, global initiatives, policy, and research collaboration and publication in oncology. Visit NCCN.org for more information.

About the NCCN Foundation
The NCCN Foundation empowers people with cancer and their caregivers by delivering unbiased expert guidance from the world’s leading cancer experts through the library of NCCN Guidelines for Patients® and other patient education resources. The NCCN Foundation is also committed to advancing cancer treatment by funding the nation’s promising young investigators at the forefront of cancer research. For more information about the NCCN Foundation, visit nccnfoundation.org.

Media Contact: 
Rachel Darwin
267-622-6624
[email protected]

Source : NCCN Expands Focus on Quality of Life and Supportive Care with New Guides for People with Cancer

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

Revenue of RMB10,670 Million in the Third Quarter, Single Quarter Revenue Back to over RMB10 Billion; Revenue of RMB29,541 Million in the First Three Quarters, Up 4.0% Year-over-Year; Excluding COVID-19 Commercial Projects, Up 23.4% Net Profit Attributable to Owners of the Company for the First Three Quarters Increased 9.5% to RMB8,076 Million; Diluted Earnings per Share (EPS) Increased 18.7% to RMB2.73 Adjusted Non-IFRS Net Profit Attributable to Owners of the Company for the First Three Quarters Increased 20.6% to RMB8,167 Million; Adjusted Non-IFRS Diluted EPS Increased 21.0% to RMB2.77[1] Free Cash Flow Continued to Increase; Operating Cash Flow Grew Strongly by 32.5% Year-Over-Year for the First Three Quarters 

SHANGHAI, Oct. 30, 2023 /PRNewswire/ — WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, is pleased to announce its financial results for the third quarter and nine months ended September 30, 2023 ("Reporting Period"): 

Revenue grew 4.0% year-over-year to RMB29,541 million; excluding COVID-19 commercial projects, revenue grew by 23.4%. Adjusted non-IFRS gross profit increased 13.8% year-over-year to RMB12,511 million. Adjusted non-IFRS gross profit margin improved 3.6pts to 42.3%. The Company continued to improve operating efficiency; adjusted non-IFRS gross profit margin increased by ~1pt year-over-year at a constant exchange rate. Net profit attributable to owners of the Company increased 9.5% year-over-year to RMB8,076 million; diluted EPS increased 18.7% year-over-year to RMB2.73. Adjusted non-IFRS net profit attributable to owners of the Company increased 20.6% year-over-year to RMB8,167 million; adjusted diluted non-IFRS EPS increased by 21.0% year-over-year to RMB2.77. Free cash flow continued to grow. Resulting from the continued profit growth, better asset utilization and efficiency improvements, the Company’s operating cash flow grew strongly by 32.5% year-over-year. In the first three quarters of 2023, we added over 900 new customers, and in total we served more than 6,000 active customers over the past 12 months. Demand from customers across regions globally continued to grow. Excluding COVID-19 commercial projects, backlog maintained growth momentum of the first half of 2023, among which TIDES backlog accelerated growth by 245% year-over-year. Revenue from the top 20 global pharmaceutical companies maintained rapid growth and reached RMB11.82 billion in the first three quarters of 2023, which grew strongly by 43% year-over-year excluding COVID-19 commercial projects. The sustained and steady revenue growth is a result of our unique fully integrated Contract Research, Development and Manufacturing Organization (CRDMO) platform. WuXi Chemistry’s D&M pipeline has maintained rapid growth, with 343 new molecules added in the third quarter and a total of 926 new molecules added in the first three quarters of the year. To date, our D&M pipeline has exceeded 3,000 molecules for the first time, currently totaling 3,014, among which 12 commercial and phase III projects were added in the first three quarters of 2023. Revenue from D&M services maintained strong growth. Excluding COVID-19 commercial projects, D&M services revenue grew by 48.2%. As an enabler of innovation, a trusted partner and a contributor to the global healthcare industry, the Company is committed to environmental protection and sustainability. We received the "AA" rating from MSCI for the third consecutive year, and upgraded to "Silver" rating by EcoVadis. Our outstanding ESG performance continues to be highly recognized by global ESG rating agencies, including MSCI, EcoVadis, S&P Global, Sustainalytics and CDP.

[1] In the first three quarters of 2022 and 2023, WuXi AppTec had a fully-diluted weighted average share count of 2,951,099,205 and 2,949,888,986 ordinary shares, respectively.

Fourth Quarter and 2023 Full Year Outlook

In the fourth quarter of 2023, revenue will all come from non-COVID-19 commercial projects. Without COVID-19 commercial projects, we expect the Company’s revenue in the fourth quarter to exceed RMB10 billion for the first time, among which WuXi Chemistry D&M will continue strong growth momentum and accelerate growth on top of the first three quarters. Excluding COVID-19 commercial projects, the Company’s revenue in the fourth quarter is projected to grow 29-34%. Excluding COVID-19 commercial projects, revenue will grow 25-26% in 2023, with the Company’s total revenue exceeding 40 billion for the first time. Due to lower than expected demand of early-stage drug discovery services, revenues from some lab service-related business will be significantly below budget. Therefore, we adjust 2023 revenue growth from 5-7% to 2-3%; excluding COVID-19 commercial projects, revenue growth from 29-32% to 25-26%.

Due to FX impact and efficiency improvements, adjusted non-IFRS gross profit margin expects to be up ~0.5pts and reach 41.7-42.1%; with further improved operating efficiency, adjusted non-IFRS net profit will exceed RMB 10 billion for the first time. Resulting from our unique CRDMO & CTDMO business model, better asset utilization and efficiency improvements, free cash flow expects to be up and reach RMB 4.5-5.0 billion, which will be over 17 times as compared to last year.

Due to lower than expected growth, the management team proactively proposes to terminate the 2023 H share incentive plan, repurchase and cancel 15,467,500 H shares, representing ~0.52% of the Company’s total share capital (worth of HKD ~1.3 billion[2]). This has been unanimously approved by the Company’s Board of Directors.

[2] Value based on the actual purchased price.

Management Comment

Dr. Ge Li, Chairman and CEO of WuXi AppTec, said, "We achieved steady growth across revenue, net profit, and free cash flow in the first three quarters of 2023, and expect the fourth-quarter revenue (without COVID-19 commercial projects) to exceed RMB10 billion for the first time. The Company’s growing pipeline and expanding customer base demonstrates heightened demand from our customers globally as they seek our services to bring new treatments to patients."

"We have constant faith in the Company’s unique CRDMO and CTDMO business models, and believe that the Company will continue solid growth in the future. WuXi AppTec is committed to meeting the growing demands from customers worldwide, enhancing our capacity and capabilities, and relentlessly pursuing operational excellence, productivity and efficiency, as we support our customers’ efforts to bring groundbreaking therapies to patients around the world. Together, we can realize our vision that ‘every drug can be made and every disease can be treated’."

Business Performance by Segments

WuXi Chemistry: Integrated CRDMO Business Model Drives Steady Growth, with Continued Expansion in New Modalities (WuXi TIDES) Q1-Q3 revenue from WuXi Chemistry grew 2.0% year-over-year to RMB 21.24 billion, excluding COVID-19 commercial projects, revenue grew strongly by 31.0%. Q1-Q3 adjusted non-IFRS gross profit margin was 45.7%, with 4.5pts year-over-year improvement, mainly due to FX impact, while efficiency continued to improve. Drug discovery services ("R") continued to generate downstream opportunities. In the past 12 months, we successfully synthesized and delivered more than 420,000 new compounds to customers, which grew 11% year-over-year. Through our "follow-the-customer" and "follow-the-molecule" strategies, we established trusted partnerships with our global customers, supporting the sustainable growth of our CRDMO business. Development and manufacturing (D&M) services delivered strong growth. In the first three quarters, D&M services revenue grew 1.4% year-over-year to RMB15.63 billion. Excluding COVID-19 commercial projects, D&M services revenue grew strongly by 48.2%. In the first three quarters, we added 926 molecules to our D&M pipeline. To date, our D&M pipeline has exceeded 3,000 molecules for the first time and reached 3,014, including 58 commercial projects, 61 in phase III, 316 in phase II and 2,579 in phase I and pre-clinical stages, among which 12 commercial and phase III projects were added in the first three quarters of 2023. Specifically, TIDES business (mainly oligo and peptides) continued to expand. In the first three quarters, TIDES revenue grew strongly by 38.1% year-over-year to RMB2.07 billion. Q4 revenue is expected to increase significantly, with TIDES full year 2023 revenue growth expected to exceed 60%. As of September 30, 2023, backlog of TIDES accelerated growth by 245% year-over-year. In the first three quarters, the number of TIDES D&M customers increased 31% year-over-year to 127, and the number of TIDES molecules increased 48% year-over-year to 230. We initiated capacity expansion in Changzhou and Taixing. The expanded workshops are expected to commence operation in December 2023, with the total reactor volume of peptide solid phase synthesizers increased from 20,000L to 32,000L. WuXi Testing: Drug Safety Evaluation Service & SMO Maintain Leadership Position and Drive Steady Growth Q1-Q3 revenue from WuXi Testing grew 16.2% year-over-year to RMB4.85 billion. Q1-Q3 adjusted non-IFRS gross profit margin was 38.6%, with 1.8pts year-over-year improvement, mainly due to FX impact, while efficiency continued to improve. Q1-Q3 2023 revenue from lab testing services grew 16.3% year-over-year to RMB3.54 billion. Among which, revenue from drug safety evaluation services grew 26.9% year-over-year. We maintained our industry leadership position in Asia Pacific for drug safety evaluation services that meet global regulatory requirements. Meanwhile, new facilities in Qidong and Suzhou have begun delivering new projects. Q1-Q3 2023 revenue from clinical CRO & SMO (Site Management Organization) grew 15.9% year-over-year to RMB1.32 billion. SMO revenue grew strongly by 31.0% in Q1-Q3 2023, maintaining a leadership position in China. In the first three quarters of 2023, SMO supported 35 new drug approvals for customers. In the first three quarters of 2023, clinical CRO enabled our customers to obtain 13 IND approvals and submit 5 NDA filings. WuXi Biology: New Modalities Business Drives Growth; WuXi Biology Platform Continues to Generate Downstream Opportunities Q1-Q3 revenue from WuXi Biology grew 6.5% year-over-year to RMB1.89 billion. Q1-Q3 adjusted non-IFRS gross profit margin was 42.8%, with 1.6pts year-over-year improvement due to FX impact. The Company focused on improving capabilities related to new modalities. In the first three quarters of 2023, WuXi Biology revenue from new modalities grew strongly by 35% year-over-year, contributing to 25.9% of WuXi Biology revenue. The comprehensive early discovery screening platform integrates multi-technologies (HTS, DEL, ASMS, FBDD, CADD etc.) and analysis capabilities of multi-dimensional databases, which can provide extensive and in-depth services to clients. In the first three quarters of 2023, it continued to generate downstream opportunities and contributed more than 20% of the Company’s new customers. WuXi ATU: CTDMO Business Model Drives Growth Q1-Q3 revenue from WuXi ATU grew 11.6% year-over-year to RMB1.03 billion. Q1-Q3 adjusted non-IFRS gross profit margin was (6.1)%, with 0.4pts year-over-year improvement due to FX impact. The Company focused on improving our CTDMO integrated enabling platform and strengthening capabilities and capacities. We provided development, testing and manufacturing services to 68 projects, including 7 Phase III projects (2 projects in BLA review stage, and 2 projects in BLA preparation stage), 9 Phase II projects and 52 pre-clinical and Phase I projects. In the first three quarters of 2023, we supported a customer to complete the BLA filing for a Tumor Infiltrating Lymphocyte (TIL) product with the FDA, which is expected to be the world’s first innovative TIL-based therapy, and our facilities in Philadelphia (U.S.) successfully passed the FDA pre-license inspection (PLI). In addition, we supported a customer to file BLA for Lenti-viral Vector (LVV) used in a CAR-T product, and became the first CGT CDMO in China to pass Center for Food and Drug Inspection of NMPA (CFDI) LVV on-site inspection. We expect that our customers will obtain approval for their products in the fourth quarter of 2023. Moreover, we completed the technology transfer for the manufacturing of a blockbuster commercial CAR-T product, whose process performance qualification is now in progress, and is expected to file pre-approval submission (PAS) to FDA in the first half of 2024. In June 2023, we signed an LVV manufacturing contract with a large pharmaceutical customer used in a commercial CAR-T product, which is expected to start manufacturing in the first half of 2024. WuXi DDSU: the First Year to Receive New Drug Application (NDA) Approval of New Drugs Developed for Customers; Breakthrough to Receive the First Royalty Income Q1-Q3 revenue from WuXi DDSU declined 26.9% year-over-year to RMB0.49 billion. Q1-Q3 adjusted non-IFRS gross profit margin was 31.6%, with 3.5pts year-over-year improvement mainly thanks to favorable project mix. In the first three quarters of 2023, 2 new drugs developed for our customers have obtained National Medical Products Administration (NMPA) approvals, including one for COVID-19 infection treatment and the other for tumor treatment. Moreover, 2 new drug candidates are in the NDA review stage. We continued to receive the royalty income of the 2 approved new drugs from customers. Royalty income is estimated to grow with more than 50% CAGR over the next 10 years as more and more products are commercialized by customers. In the first three quarters of 2023, we supported customers to file INDs for 15 drug candidates and obtain 19 Clinical Trial Approvals (CTAs). Cumulatively, we have submitted 187 new chemical entity IND filings and obtained 163 CTAs for customers, among which 2 projects have obtained NDA approvals, 2 projects are in the NDA review stage, 5 projects are in Phase III, 29 projects are in Phase II, and 70 projects are in Phase I, covering multiple therapeutic areas.

This release provides a summary of the results and is not intended to be a comprehensive report. For additional information, please refer to the WuXi AppTec 2023 Third Quarterly Results Presentation and 2023 Third Quarterly Report disclosed on the Company’s official website, as well as the 2023 Third Quarterly Report and other relevant announcements published on the websites of the Shanghai Stock Exchange (www.sse.com.cn) and the Stock Exchange of Hong Kong (www.hkexnews.hk), and the designated media for dissemination of the relevant information. Investors are advised to exercise caution and be aware of the investment risks in trading Company shares.

All financial information disclosed in this press release is prepared based on International Financial Reporting Standards (IFRS), in currency of RMB.

The 2023 Third Quarterly Report of the Company has not been audited.

Third Quarter 2023 Results by Segments

Unit: RMB million

Segment

Revenue

Change

Adjusted non-
IFRS Gross Profit

Change

Adjusted non-
IFRS Gross
Profit Margin

WuXi
Chemistry

7,774.18

(0.9) %

3,613.59

10.8 %

46.5 %

WuXi Testing

1,763.24

12.2 %

706.55

15.4 %

40.1 %

WuXi Biology

662.28

(3.8) %

299.37

4.0 %

45.2 %

WuXi ATU

314.63

2.7 %

(22.29)

Note1

(7.1) %

WuXi DDSU

149.11

(31.2) %

52.16

6.1 %

35.0 %

Others

6.60

(45.2) %

6.57

(1.7) %

99.6 %

Total

10,670.04

0.3 %

4,655.96

10.8 %

43.6 %

Notes: 1. Adjusted non-IFRS gross profit of WuXi ATU was RMB(22.29) million in Q3 2023, compared to
RMB(16.87) million in Q3 2022, a decline of RMB5.41 million.

2. Any sum of the data above that is inconsistent with the total is due to rounding.

Year-to-Date 2023 Results by Segments

Unit: RMB million

Segment

Revenue

Change

Adjusted non-
IFRS Gross
Profit

Change

Adjusted non-
IFRS Gross
Profit Margin

WuXi
Chemistry

21,241.39

2.0 %

9,716.99

13.3 %

45.7 %

WuXi Testing

4,854.24

16.2 %

1,874.64

21.8 %

38.6 %

WuXi Biology

1,894.91

6.5 %

810.47

10.7 %

42.8 %

WuXi ATU

1,028.25

11.6 %

(62.64)

Note1

(6.1) %

WuXi DDSU

491.10

(26.9) %

155.16

(17.8) %

31.6 %

Others

31.43

12.3 %

15.97

7.3 %

50.8 %

Total

29,541.33

4.0 %

12,510.58

13.8 %

42.3 %

Notes: 1. Adjusted non-IFRS gross profit of WuXi ATU was RMB(62.64) million in the first three quarters of 2023,
compared to RMB(59.62) million in the same period of 2022, a decline of RMB3.03 million.

2. Any sum of the data above that is inconsistent with the total is due to rounding.

Consolidated Statement of Profit or Loss[3]

RMB Million

Three Months Ended
September 30,

Nine Months Ended
September 30,

2023

2022

2023

2022

Revenue

10,670.0

10,638.3

29,541.3

28,394.6

Cost of services

(6,154.3)

(6,600.2)

(17,469.9)

(17,929.6)

Gross profit

4,515.8

4,038.1

12,071.5

10,464.9

Other income

182.9

113.3

622.7

353.8

Other gains and losses

14.9

668.4

1,076.0

2,058.3

Impairment losses under expected credit losses
 ("ECL") model, net of reversal

(31.1)

(35.2)

(132.8)

(94.0)

Impairment losses recognized on non-financial assets

–

–

(42.9)

–

Selling and marketing expenses  

(167.7)

(199.7)

(521.2)

(555.3)

Administrative expenses 

(732.5)

(791.3)

(2,059.0)

(2,099.2)

R&D expenses

(358.8)

(432.1)

(1,025.8)

(1,089.3)

Operating Profit

3,423.4

3,361.5

9,988.5

9,039.4

Share of results of associates

18.1

(36.0)

(58.4)

(106.8)

Share of results of joint ventures

(0.9)

(1.9)

6.8

(0.4)

Finance costs

(53.9)

(45.3)

(154.9)

(112.9)

Profit before tax

3,386.8

3,278.4

9,782.0

8,819.3

Income tax expense

(595.0)

(507.4)

(1,633.3)

(1,372.7)

Profit for the period

2,791.8

2,771.0

8,148.6

7,446.6

Profit for the period attributable to:

Owners of the Company

2,763.3

2,742.2

8,076.4

7,377.9

Non-controlling interests

28.5

28.8

72.2

68.7

2,791.8

2,771.0

8,148.6

7,446.6

[3] If the sum of the data below is inconsistent with the total, it is caused by rounding

Consolidated Statement of Profit or Loss[4]

Three Months Ended

September 30,

Nine Months Ended

September 30,

2023

2022

2023

2022

Weighted average number of ordinary shares for
calculating EPS (express in shares)

– Basic

2,935,018,668

2,933,269,400

2,936,228,550

2,926,045,926

– Diluted

2,945,931,775

2,953,335,314

2,949,888,986

2,951,099,205

Earnings per share attributable to ordinary
shareholders of the Company (expressed in RMB per
share)

– Basic

0.94

0.93

2.75

2.52

– Diluted

0.94

0.81

2.73

2.30

[4] If the sum of the data below is inconsistent with the total, it is caused by rounding

Consolidated Statement of Financial Position[5]

RMB Million

September 30,

December 31,

2023

2022

Non-current Assets

Property, plant and equipment

25,014.6

23,444.9

Right-of-use assets

2,246.1

1,857.5

Goodwill

1,872.1

1,822.1

Other intangible assets

947.1

926.3

Interests in associates

1,087.7

1,135.7

Interests in joint ventures

75.2

67.3

Deferred tax assets

622.5

492.1

Financial assets at fair value through profit or
   loss ("FVTPL")

8,887.9

8,954.3

Other non-current assets

101.9

1,054.9

Biological assets

1,127.0

938.0

41,982.1

40,693.1

Current Assets

Inventories

3,413.5

3,952.6

Contract costs

731.7

678.8

Biological assets

1,148.3

1,037.3

Amounts due from related parties

64.7

123.0

Trade and other receivables

8,794.4

7,590.4

Contract assets

1,276.7

1,048.2

Income tax recoverable

–

16.0

Financial assets at FVTPL

3,210.1

2.0

Derivative financial instruments

14.3

135.6

Other current assets

1,675.0

1,427.8

Pledged bank deposits

2.2

1.8

Bank balances and cash

9,446.4

7,983.9

29,777.2

23,997.2

Total Assets

71,759.3

64,690.3

[5] If the sum of the data below is inconsistent with the total, it is caused by rounding.

Consolidated Statement of Financial Position (continued)[6]

RMB Million

September 30,

December 31,

2023

2022

Current Liabilities

Trade and other payables

7,553.3

7,253.4

Amounts due to related parties

7.6

14.5

Derivative financial instruments

1,154.6

115.4

Contract liabilities

2,297.2

2,496.6

Borrowings

4,639.1

3,874.1

Lease liabilities

192.8

205.3

Income tax payables

1,134.7

517.8

Other current liabilities

–

22.1

16,979.1

14,499.4

Non-current Liabilities

Borrowings

356.6

279.1

Deferred tax liabilities

399.1

440.5

Deferred income

963.8

910.9

Lease liabilities

1,072.2

983.8

Convertible bonds-debt component

–

502.0

Convertible bonds-embedded derivative
   component

–

147.9

Other long-term liabilities

–

0.1

2,791.7

3,264.3

Total Liabilities

19,770.9

17,763.7

Net Assets

51,988.4

46,926.7

Capital and Reserves

Share capital 

2,968.7

2,960.5

Reserves

48,618.0

43,629.4

Equity attributable to owners of the Company

51,586.7

46,590.0

Non-controlling interests

401.7

336.7

Total Equity

51,988.4

46,926.7

[6] If the sum of the data below is inconsistent with the total, it is caused by rounding.

Adjusted Non-IFRS Net Profit Attributable to the Owners of the Company[7]

RMB Million

Three Months Ended

September 30,

Nine Months Ended

September 30,

2023

2022

2023

2022

Net profit attributable to the owners of the Company

2,763.3

2,742.2

8,076.4

7,377.9

Add:

      Share-based compensation expenses

156.2

143.4

480.6

503.4

      Issuance expenses of convertible bonds

–

0.4

0.3

1.3

      Fair value gain from derivative component of
        convertible bonds

–

(342.5)

(40.2)

(617.1)

      Foreign exchange related gains

(18.3)

(207.4)

(354.8)

(365.9)

      Amortization of intangible assets acquired from merge
        and acquisition

14.8

13.8

43.3

42.5

      Non-financial assets impairment

–

–

42.9

–

Non-IFRS Net Profit attributable to the owners of the
   Company

2,916.0

2,349.9

8,248.5

6,942.1

Add:

      Realized and unrealized losses (gains) from venture
        capital investments

155.6

119.7

(74.6)

(170.4)

      Realized and unrealized share of losses (gains) from
        joint ventures

0.9

1.9

(6.8)

0.4

Adjusted non-IFRS net profit attributable to the owners of
   the Company

3,072.4

2,471.5

8,167.1

6,772.2

[7] If the sum of the data below is inconsistent with the total, it is caused by rounding.

About WuXi AppTec

As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI in 2022 and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated." Please visit: http://www.wuxiapptec.com

Forward-Looking Statements

This press release may contain certain "forward-looking statements" which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, the ability of our service offerings to compete effectively, our ability to meet timelines for the expansion of our service offerings, our ability to protect our customers’ intellectual property, unforeseeable international tension, competition, the impact of emergencies and other force majeure. Our forward-looking statements in this press release speak only as of the date on which they are made, and we assume no obligation to update any forward-looking statements except as required by applicable law or listing rules. Accordingly, you are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section. All information provided in this press release is as of the date of this press release and are based on assumptions that we believe to be reasonable as of this date, and we do not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Use of Non-IFRS and Adjusted Non-IFRS Financial Measures

We provide non-IFRS gross profit and non-IFRS net profit attributable to owners of the Company, which exclude share-based compensation expenses, issuance expenses of convertible bonds, fair value gain or loss from derivative component of convertible bonds, foreign exchange-related gains or losses, amortization of intangible assets acquired in business combinations, non-financial assets impairment, etc. We also provide adjusted non-IFRS net profit attributable to owners of the Company and earnings per share, which further exclude realized and unrealized gains or losses from our venture capital investments and joint ventures. Neither is required by, or presented in accordance with IFRS.

We believe that the adjusted financial measures used in this press release are useful for understanding and assessing our core business performance and operating trends, and we believe that management and investors may benefit from referring to these adjusted financial measures in assessing our financial performance by eliminating the impact of certain unusual, non-recurring, non-cash and non-operating items that we do not consider indicative of the performance of our core business. Such adjusted non-IFRS net profit attributable to owners of the Company, the management of the Company believes, is widely accepted and adopted in the industry the Company is operating in. However, the presentation of these adjusted non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with IFRS. You should not view adjusted results on a stand-alone basis or as a substitute for results under IFRS, or as being comparable to results reported or forecasted by other companies.

Source : WuXi AppTec Continued Solid Growth in the First Three Quarters of 2023 on Top of an Exceptionally Strong Year in 2022, with Profit Growth Continuously Exceeding Revenue Growth

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network